MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/03007995.2020.1846510

Медицинская библиотека · Current medical research and opinion · 2020

The disease burden of mucormycosis in Japan: results from a systematic literature review and retrospective database study.

Ueno Rie, Nishimura Shinichi, Fujimoto Go, Ainiwaer Dilinuer

СтатьяПоддержка исследования: вне правительства СШАСистематический обзорПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate outcomes, healthcare resource utilization, and costs associated with mucormycosis in inpatient settings in Japan.

METHODS

We performed a systematic literature review, followed by a retrospective database study using hospital health claims for patients in Japan hospitalized with a diagnosis of mucormycosis between January 2010 and January 2019. Outcomes assessed included duration of index hospitalization; index stay mortality; hospital readmission within 30, 60, and 90 days after index hospitalization discharge; drug/treatment utilization and patterns; number of patients examined for mucormycosis during the index hospitalization; and index stay inpatient costs.

RESULTS

From our systematic literature review of articles describing 133 patients with mucormycosis, mortality in the index hospitalization was 55.6%. From our database study of 126 patients hospitalized for mucormycosis, mortality during the index hospitalization was 35.7% and mean index stay duration was 94 days. Hematologic malignancies were the most common risk factor in the literature review and the most common comorbidity in the database study. During the index stay, 39 patients (31.0%) received liposomal amphotericin B (L-AMB) treatment and 74 patients (58.7%) received other antifungal treatments. Median total inpatient costs for the index hospitalization were equivalent to approximately US$60,945, including US$29,283 in drug costs.

CONCLUSIONS

This study investigated the healthcare resource utilization and cost of medical resources caused by mucormycosis in Japan. The drug costs for antifungal treatments comprised about half of total inpatient costs. Mucormycosis leads to high mortality, high healthcare resource utilization, and high costs.

Для цитирования: Ueno Rie, Nishimura Shinichi, Fujimoto Go, Ainiwaer Dilinuer. The disease burden of mucormycosis in Japan: results from a systematic literature review and retrospective database study.. Current medical research and opinion. 2020. DOI: 10.1080/03007995.2020.1846510.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.